Moderate Dietary Supplementation with Omega-3 Fatty Acids Does Not Impact Plasma Von Willebrand Factor Profile in Mildly Hypertensive Subjects

Figure 2

Plasma von Willebrand factor (vWF) concentration at baseline and after 12 weeks of treatment with 2.52 g/day long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs). Initial vWF concentration (international units/mL) was not different for hypertensive and normotensive subjects (a). The 12-week supplementation protocol with LC n-3 PUFAs had no effect on plasma concentration of vWF in normotensive and hypertensive subjects (b). Data are expressed as mean ± SEM. HT, hypertensive; NT, normotensive; n-3, LC n-3 PUFAs.

(a)

(b)